List view / Grid view
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
20 October 2023 | By Eurofins Discovery
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
Tune into this podcast to hear experts discussing the tumour microenvironment in immuno-oncology!
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
Scientists have developed a promising new method to detect cancer at very early stages during routine health screens, paving way for improved treatment and recovery.
Researchers from UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine have made a discovery linking the notorious cancer-causing gene, Myc, to the process of ageing.
Important step achieved by US researchers as stable and potent immune therapy delivery system eradicates tumours in mouse models of melanoma, colon, and breast cancer, while preventing the formation of future tumour.
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.
14 July 2023 | By BPS Bioscience
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
A combination of radiotherapy followed by immunotherapy is a promising strategy for the treatment of oral malignant melanomas in dogs.
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
